Dr. Marcelo Di Carli, a radiology professor at Harvard Medical School, says a number of radiopharmaceuticals under development hold potential for cardiac imaging. PET agent F-18 flurpiridaz has shown high myocardium extraction in midstage clinical studies, and it can be distributed on a unit-dose basis, meaning it would be available to more practices and patients. Meanwhile, iodine-123 metaiodobenzylguanidine, which is being developed for SPECT imaging, may be effective in improving risk stratification for heart failure patients, Di Carli added. The approach evaluates cardiac sympathetic innervation. Agents that measure proteins linked to inflammation in atherosclerotic plaques are also coming.
What's coming in cardiovascular imaging?
SmartBrief Job Listings for Health Care
|Director of Contracting and Compliance||
CareFirst BlueCross BlueShield
|Multiple Locations, MD|
|Behavioral Health Services Director||
|President and CEO||
|Manager of Provider Network Analytics||
Geisinger Health System
Yakima Valley Farm Workers Clinic